Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gold Fields Limited (GFI) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Gold Fields LimitedTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Gold Fields Limited vs IDEXX Laboratories, Inc. — how do they compare? Gold Fields Limited trades at $36.82 (market cap $31.87B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Gold Fields Limited pays a 6% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and IDEXX Laboratories, Inc. for 46 Days on average.

GFIIDXX
Market Cap
$31.87B$40.43B
Volume
4,169,651692,164
Sector
Basic MaterialsHealth
52-Week High
$61.52$766.68
52-Week Low
$31.25$504.70
Typical Hold Time
49 Days46 Days
Enterprise Value
$32.47B$41.32B
Dividend Yield
6%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gold Fields Limited

Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal but strong fundamentals. Revenue surged to $8.75B in 2025 with a net income margin of 38.66%, while valuation ratios like a P/E of 7.3 and EV/EBITDA of 4.64 suggest undervaluation. Recent news centers on a rejected $27B bid for Northern Star, causing volatility, but operational performance remains robust with record cash flow.

The outlook is mixed: analyst consensus is a Buy with a $52.75 price target, but technicals are bearish and earnings misses pose near-term risks. Upside hinges on execution of growth projects and gold price stability, while acquisition-related uncertainty and debt levels warrant caution for investors.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.

Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GFI
11% Buy89% Sell
Avg holding period · 49 Days
IDXX

No sentiment data available yet.

About Gold Fields Limited

Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.

Read more on GFI →

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →